

## DAFTAR PUSTAKA

1. Chang T, Wu J, Chang L. Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis. *J Formos Med Assoc.* 2020;119:982-89
2. Dhama K, Khan S, Tiwari R et al. Coronavirus Disease 2019 –COVID-19. *Clin Microbiol Rev.* 2020;33(4):1–48.
3. Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerg Microbes Infect.* 2020;9(1):221–36.
4. Susilo A, Rumende CM, Pitoyo CW et al. Coronavirus Disease 2019: Review of Current Literatures. *J Penyakit Dalam Indones.* 2020;7(1):45.
5. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J. Autoimmun.* 2020;1-4.
6. Terpos E, Stathopoulos IN, Elalamy I et al. Hematological findings and complications of COVID-19. *Am J Hematol.* 2020;1–14
7. Rasyid H, Sangkereng A, Harjianti T, Soetjipto AS. Impact of age to ferritin and neutrophil-lymphocyte ratio as biomarkers for intensive care requirement and mortality risk in COVID-19 patients in Makassar, Indonesia. *Physiol Rep* [Internet]. 2021;9(10):e14876. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34042296>
8. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA,

- et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020;5(4):536–44.
9. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. *J Pharm Anal.* 2020;10(2):102–8.
  10. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med* [Internet]. 2020;46(4):586–90. Available from: <https://doi.org/10.1007/s00134-020-05985-9>
  11. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *J Travel Med.* 2020;27(2):1–4.
  12. De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. *Nat Rev Microbiol.* 2016;14(8):523–34.
  13. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. *Proc Natl Acad Sci U S A.* 2004;101(12):4240–5.
  14. Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. *Cell Res.* 2008;18(2):290–301.

15. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. *J Med Virol* [Internet]. 2020;92(4):424–32. Available from: <http://dx.doi.org/10.1002/jmv.25685>
16. Mózo BS. Dysregul. *J Chem Inf Model* [Internet]. 2017;53(9):1689–99. Available from: <file:///C:/Users/User/Downloads/fvm939e.pdf>
17. Fan YY, Huang ZT, Li L, Wu MH, Yu T, Koup RA, et al. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. *Arch Virol*. 2009;154(7):1093–9.
18. Burhan E, Susanto AD, Nasution SA et al. Pedoman tatalaksana COVID-19. *PDPI*. 2022;4:9-10
19. Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. *Int J Lab Hematol*. 2020;42(S1):11–8.
20. Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. *Am J Hematol*. 2020;95(6):E131–4.
21. Lai AL, Millet JK, Daniel S, Freed JH, Whittaker GR. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- company ’ s public news and information website . Elsevier hereby grants permission to make all its COVID-19-r. *Lancet*. 2020;395(April):1315.
22. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus

COVID- research that is available on the COVID-19 resource centre - including this for unrestricted research re-use a. 2020;(January):19–21.

23. Amgalan A, Othman M. Exploring possible mechanisms for COVID-19 induced thrombocytopenia: Unanswered questions. *J Thromb Haemost.* 2020;18(6):1514–6.
24. Lippi G, Plebani M, Henry BM et al. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta.* 2020;506:145–8.
25. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. *Ann Hematol.* 2020;99(6):1205–8.
26. Channappanavar R, Perlman S. Pathogenic human corona virus infections: cause and consequences of cytokine storm and immunopathology. *Semin Immunopathol.* 2017.39(5):529-39
27. Imran, M. M., Ahmed, U., Usman, U., Ali, M., Shaukat, A., & Gul, N. (2020). Neutrophil/lymphocyte ratio – A marker of COVID-19 pneumonia severity. *International Journal of Clinical Practice*, 75(4), 1–15.
28. Guan W, Ni Z, Liang W et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *NEJM.* 2020.1-13.
29. Zhao Q, Meng M, Kumar R et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. *International Journal of Infectious Diseases* 96 (2020) 131–135
30. Qin C, Zhou L, Hu Z et al. Dysregulation of immune response in patients

with Covid-19 in Wuhan, China. *Clin Infect Dis.* 2020;1-24

- 31 Shang W, Dong J, Ren et al. The value of clinical parameters in predicting the severity of COVID-19. *J. Med. Virol.* 2020;92:2188–2192.